Regeneron
6,141
$617.109876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$617.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$4.98 (-0.80%) Today
+$1.22 (+0.20%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell Regeneron and other stocks, options, ETFs, and crypto commission-free!
About REGN
Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Read More It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Employees
8,100
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
69.30B
Price-Earnings Ratio
31.20
Dividend Yield
—
Average Volume
1.09M
High Today
$633.84
Low Today
$614.37
Open Price
$623.67
Volume
733.43K
52 Week High
$655.93
52 Week Low
$271.37
Collections
REGN News
BenzingaJul 11
Barron's Picks And Pans: Facebook, Nokia, Regeneron And More
This weekend's Barron's cover story presents the results from the Barron's 2020 Midyear Roundtable.
Other featured articles look how to manage risk in a time o
Analyst Ratings
56%
of 27 ratings
Buy
56%
Hold
41%
Sell
4%
REGN Earnings
$0.00
$2.50
$5.00
$7.50
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
— per share
Actual
Available Aug 5, Pre-Market
You May Also Like
More REGN News
The EconomistJul 8
The Economist explains - Can antibody therapies control covid-19?
THIS WEEK an American pharmaceutical company, Regeneron, announced that it had a new drug for covid-19 entering late-stage clinical trials. This is one of sever
BenzingaJul 7
Why Regeneron's Stock Is Trading Higher Today
Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher on Tuesday after the company announced it has been awarded a $450 million contract to manufac
CNBCJul 7
Regeneron signs a $450 million contract with the U.S. government for its coronavirus therapy
Regeneron Pharmaceuticals said on Tuesday the U.S. government signed a $450 million contract with the drugmaker to make and supply its potential double-antibody
CNBCJul 7
Stocks making the biggest moves in the premarket: Novavax, Regeneron, Square, Nvidia & more
Take a look at some of the biggest movers in the premarket:
Novavax (NVAX) – Novavax was awarded $1.6 billion in funding from "Operation Warp Speed," the gover
